IPO, Metsera

Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO
Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable appetite for such treatments.
Metsera eyes $289M IPO to fund phase 3 weight loss trial
Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its GLP-1 receptor agonist. | Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its GLP-1 receptor agonist.
GLP-1RA developer Metsera targets $289m IPO
Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.
Weight-loss drug developer Metsera raises $275 million in US IPO
Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company said on Thursday.
Metsera Seeks $289M Raise, $1.78B Valuation in IPO
The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.
Obesity drug developer Metsera sets terms for $275M IPO
Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. In a recent SEC filing, Metsera (MTSR) said it was looking to offer 17.
Weight-loss drug developer Metsera seeks up to $1.78 billion valuation in US IPO
Weight-loss drug developer Metsera is targeting an up to $1.78 billion valuation in its initial public offering, the ARCH Venture Partners-backed biotech company said on Monday. New York City-based Metsera seeks to raise up to $292.
Metsera Readies $275 Million IPO For Obesity Treatments
Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...
Metsera, Inc IPOs Tomorrow, Here's What You Need To Know
Metsera, Inc MTSR IPO will take place January, 31 on the NASDAQ exchange under the ticker MTSR. The company is offering shares at an expected price between $15.00 and $17.00 per share with an insider ...
Google Ventures-Backed Biotech Metsera Seeks $292 Million in IPO
Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to ...
ENDPOINTS NEWS3d
Met­sera out­lines $250M IPO plans as obe­si­ty biotech com­pe­ti­tion ris­es
Metsera, a well-funded biotech trying to angle toward the front of the obesity medicine pack, has proposed a $250 million IPO ...
FierceBiotech6d
‘A really rational IPO environment’: What does it takes for a biotech to go public now?
After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...